Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
SFOSF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $41,067,196 | $41,399,540 | $43,951,547 | $39,005,087 |
| % Growth | -0.8% | -5.8% | 12.7% | – |
| Cost of Goods Sold | $21,365,574 | $21,595,309 | $23,169,690 | $20,228,269 |
| Gross Profit | $19,701,622 | $19,804,231 | $20,781,856 | $18,776,817 |
| % Margin | 48% | 47.8% | 47.3% | 48.1% |
| R&D Expenses | $3,644,356 | $4,346,045 | $4,302,093 | $3,834,483 |
| G&A Expenses | $1,113,940 | $1,174,843 | $988,062 | $846,109 |
| SG&A Expenses | $6,473,035 | $7,372,870 | $10,159,238 | $9,945,001 |
| Sales & Mktg Exp. | $5,359,095 | $6,198,027 | $9,171,176 | $9,098,892 |
| Other Operating Expenses | $5,339,126 | $4,777,809 | $2,683,686 | $2,276,352 |
| Operating Expenses | $15,456,518 | $16,496,723 | $17,145,017 | $16,055,836 |
| Operating Income | $4,245,104 | $3,307,508 | $8,296,573 | $6,313,736 |
| % Margin | 10.3% | 8% | 18.9% | 16.2% |
| Other Income/Exp. Net | -$75,822 | -$42,940 | -$1,917,421 | -$2,049,035 |
| Pre-Tax Income | $4,169,282 | $3,264,568 | $4,574,382 | $6,053,838 |
| Tax Expense | $656,841 | $369,504 | $626,917 | $1,066,400 |
| Net Income | $2,769,887 | $2,386,266 | $3,730,805 | $4,728,711 |
| % Margin | 6.7% | 5.8% | 8.5% | 12.1% |
| EPS | 1.04 | 0.89 | 1.43 | 1.85 |
| % Growth | 16.9% | -37.8% | -22.7% | – |
| EPS Diluted | 1.04 | 0.89 | 1.43 | 1.85 |
| Weighted Avg Shares Out | 2,663,353 | 2,681,198 | 2,607,380 | 2,562,899 |
| Weighted Avg Shares Out Dil | 2,663,353 | 2,681,198 | 2,607,385 | 2,562,899 |
| Supplemental Information | – | – | – | – |
| Interest Income | $373,210 | $363,645 | $282,635 | $233,727 |
| Interest Expense | $1,431,915 | $1,324,831 | $963,807 | $822,534 |
| Depreciation & Amortization | $3,001,543 | $3,118,678 | $2,447,606 | $1,948,448 |
| EBITDA | $8,602,739 | $5,559,393 | $7,874,100 | $8,813,652 |
| % Margin | 20.9% | 13.4% | 17.9% | 22.6% |